Ginkgo Bioworks Holdings, Inc. 8-K

What Happened Ginkgo Bioworks Holdings, Inc. announced the results of its annual meeting of shareholders held on June 11, 2026. A total of 39,536,848 shares of Class A and 8,405,525 shares of Class B common stock were present or represented by proxy (≈77.15% of combined voting shares; ≈93.77% of Class B). Class A shares carry one vote per share; Class B carry ten votes per share. Six director nominees were elected: Jason Kelly and Reshma Shetty (elected by Class B holders), and Ross Fubini, Christian Henry, Sri Kosuri, and Harry E. Sloan (elected by Class A and Class B voting together). Deloitte & Touche LLP was ratified as the company’s independent registered public accounting firm for the 2026 fiscal year, and the advisory (non-binding) vote to approve named executive officer compensation passed.

Key Details

• Meeting date: June 11, 2026; 39,536,848 Class A and 8,405,525 Class B shares represented.
• Director votes (selected totals): Jason Kelly and Reshma Shetty — 84,007,040 For; 48,210 Against. Ross Fubini — 100,125,571 For; 7,977,143 Against; 3,696,487 Abstentions.
• Auditor ratification: Deloitte & Touche LLP approved — 119,527,721 For; 267,727 Against; 3,796,650 Abstentions.
• Advisory vote on executive compensation: 95,058,585 For; 12,502,153 Against; 4,238,463 Abstentions.

Why It Matters These outcomes confirm the company’s board composition and continued use of Deloitte as its independent auditor, both of which affect corporate oversight and financial reporting. The affirmative advisory vote on executive compensation indicates shareholder support for the company’s pay practices (though advisory only). High representation of Class B voting power (10 votes per share) underscores the influence of Class B holders in director elections and corporate control decisions.